Related Experiment Videos
Chemotherapy of non-Hodgkin's aggressive lymphomas
G Salles1, M A Shipp, B Coiffier
1Service d'Hématologie, Hospices Civils de Lyon, Université Claude Bernard, France.
Seminars in Hematology
|January 1, 1994
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study.
Journal of cancer research and clinical oncology·2021
Acute renal and splenic infarctions: a review.
QJM : monthly journal of the Association of Physicians·2019
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials.
Annals of oncology : official journal of the European Society for Medical Oncology·2018
Role of up-front autologous stem-cell transplantation in peripheral T-cell lymphoma for patients in response after induction: an analysis of patients from LYSA centers.
Annals of oncology : official journal of the European Society for Medical Oncology·2017
EZH2 alterations in follicular lymphoma: biological and clinical correlations.
Blood cancer journal·2017
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
Annals of oncology : official journal of the European Society for Medical Oncology·2017
Germline predisposition in myeloproliferative neoplasms.
Seminars in hematology·2026
Alloimmunization in sickle cell disease: Addressing an ongoing clinical challenge.
Seminars in hematology·2026
Pain in SCD-Many mechanisms and mysteries.
Seminars in hematology·2026
Feasibility of Single-Session Whole-Liver Yttrium-90 Radioembolization for Multifocal Hepatocellular Carcinoma.
Korean journal of radiology·2026
Cemiplimab in cutaneous squamous cell carcinoma: a longer follow-up study focusing on the late toxicities.
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Not all anti-CD38 antibodies are created equal: The epitope of felzartamab is partially DTT-resistant.
Transfusion medicine (Oxford, England)·2026